Treatment of Patients With Recurrent Coronary In-stent Restenosis With Failed Intravascular Brachytherapy.

MedStar author(s):
Citation: American Journal of Cardiology. 142:44-51, 2021 03 01.PMID: 33285089Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Angioplasty, Balloon, Coronary/mt [Methods] | *Brachytherapy/mt [Methods] | *Coronary Restenosis/th [Therapy] | *Drug-Eluting Stents | *Percutaneous Coronary Intervention/mt [Methods] | Aged | Endovascular Procedures | Female | Humans | Male | Middle Aged | Mortality | Myocardial Infarction/ep [Epidemiology] | Myocardial Revascularization/sn [Statistics & Numerical Data] | Recurrence | Retreatment | Treatment FailureYear: 2021Local holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006ISSN:
  • 0002-9149
Name of journal: The American journal of cardiologyAbstract: Intravascular brachytherapy (VBT) is an effective and safe treatment option for recurrent drug-eluting stent (DES) in-stent restenosis (ISR). However, the optimal therapy for patients with failed VBT is not well-defined. In this study, we sought to evaluate the optimal treatment strategy for patients after a failed VBT. Patients with recurrent ISR after an initial unsuccessful VBT were identified from our percutaneous coronary intervention database. Patients were divided into 2 cohorts (standard treatment with DES or balloon angioplasty vs. repeat VBT). Baseline characteristics and clinical outcomes during follow-up were extracted. A total of 279 patients underwent PCI after an initial unsuccessful VBT at our institution. Of those, 215 (77%) patients underwent standard treatment with balloon angioplasty with or without DES, and 64 (33%) underwent balloon angioplasty followed by repeat VBT. The mean age of the cohort was 64+/-11 years. Overall, 71% were men, 47% had diabetes, and 22% had heart failure. The majority (64%) presented with unstable angina. The groups had similar baseline characteristics. The rate of major adverse cardiovascular events (MACE, defined as all-cause mortality, myocardial infarction, or target vessel revascularization) was significantly lower in the repeat VBT group at 1 year (31% vs. 14%, p=0.03), 2 years (51% vs. 31%, p=0.03), and 3 years (57% vs 41%, p=0.08). Target lesion revascularization and target vessel revascularization were consistently lower in the repeat VBT group at all follow-up intervals than in the standard treatment group. Treatment of recalcitrant ISR following an initial failed VBT is associated with a high MACE rate at 3-year follow-up. Repeat VBT is safe and effective and should be considered as the preferred strategy. Copyright (c) 2020. Published by Elsevier Inc.All authors: Ben-Dor I, Case BC, Chen Y, Forrestal BJ, Satler LF, Shea C, Torguson R, Waksman R, Yerasi C, Zhang COriginally published: American Journal of Cardiology. 2020 Dec 04Fiscal year: FY2021Digital Object Identifier: Date added to catalog: 2020-12-31
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 33285089 Available 33285089

Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006

Intravascular brachytherapy (VBT) is an effective and safe treatment option for recurrent drug-eluting stent (DES) in-stent restenosis (ISR). However, the optimal therapy for patients with failed VBT is not well-defined. In this study, we sought to evaluate the optimal treatment strategy for patients after a failed VBT. Patients with recurrent ISR after an initial unsuccessful VBT were identified from our percutaneous coronary intervention database. Patients were divided into 2 cohorts (standard treatment with DES or balloon angioplasty vs. repeat VBT). Baseline characteristics and clinical outcomes during follow-up were extracted. A total of 279 patients underwent PCI after an initial unsuccessful VBT at our institution. Of those, 215 (77%) patients underwent standard treatment with balloon angioplasty with or without DES, and 64 (33%) underwent balloon angioplasty followed by repeat VBT. The mean age of the cohort was 64+/-11 years. Overall, 71% were men, 47% had diabetes, and 22% had heart failure. The majority (64%) presented with unstable angina. The groups had similar baseline characteristics. The rate of major adverse cardiovascular events (MACE, defined as all-cause mortality, myocardial infarction, or target vessel revascularization) was significantly lower in the repeat VBT group at 1 year (31% vs. 14%, p=0.03), 2 years (51% vs. 31%, p=0.03), and 3 years (57% vs 41%, p=0.08). Target lesion revascularization and target vessel revascularization were consistently lower in the repeat VBT group at all follow-up intervals than in the standard treatment group. Treatment of recalcitrant ISR following an initial failed VBT is associated with a high MACE rate at 3-year follow-up. Repeat VBT is safe and effective and should be considered as the preferred strategy. Copyright (c) 2020. Published by Elsevier Inc.

English

Powered by Koha